TLSI
TriSalus Life SciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The better read-through from Q1 is that the core platform still showed 86.2% gross margin, cash rose to $56.6 million after the $46 million raise, and management kept layering real-world PEDD evidence plus a visible second-half data calendar. If the commercial reset was genuinely temporary and TriNav Advance clears in 2H26, the current equity value leaves room for a sharper rerating than a normal medtech quarter would imply [#PR-2026-05-12].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +7.3.
What can break
2026 revenue guidance was reduced to $54 million-$57 million after Q1 revenue of $8.9 million missed the prior growth trajectory.
Momentum
62
Value
41
Sentiment
17
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.10 · Bull $4.75 · Bear $1.50
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $9.00
Why
Momentum62 · Δ7d +7.3
Value41 · Δ7d -0.1
Sentiment17 · Δ7d -4.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
62
26% active weight
Current posture
7d trendImproving
Δ7d
+7.3
Δ21d
+17.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
17
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.4
Δ21d
+4.8
Why this grade
Composite grade F. Momentum 61.7 / Value 41.1 / Sentiment 17.3
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$264.7M
Beta
0.43
Shares Out
61.42M
P/E (TTM) · Derived
-2.3
P/S (TTM)
7.59
P/FCF (TTM) · Derived
-8.77
Rev YoY
-2.9%
EPS YoY
-107.6%
Gross Margin
+85.1%
Op Margin
-77.7%
Net Debt
$14M
Current Ratio
5.78
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology